Unleashing the power of RNAi to create precise, durable therapeutics.
We are a cross-disciplinary group of entrepreneur-scientists that came together in 2020 to usher in the next generation of RNAi technologies. Coming from leading academic institutions, well-established pharma companies, and high-stress military environments, we share the single goal of creating scalable processes to program RNAi therapies, focusing initially on treating respiratory diseases.
Setting up three collaborative hubs - in Cambridge, UK; Boston, U.S.; and Tel Aviv, Israel - we have tapped into some of the world’s top talent pools. In addition, we are partnering with leading institutions, including the Vaccine Research Center at the NIAID, Cambridge University, Twist Biosciences, and Biotage.
We are living through a biological revolution. The past decade has witnessed the advent of massively-parallel synthesis of DNA, high-throughput sequencing, genomic discoveries, and machine learning.
Yet, the development of therapies typically relies on a slow process of trial and error.
At Eleven Tx, we orchestrate these technologies into highly-efficient processes for mapping the vast combinatorial space of potential RNAi molecules, and precisely program the next generation of RNAi therapeutics. Capitalizing on these capabilities, we create tailor-made therapeutics that precisely silence disease-causing genes, treating the root cause of illnesses in humans.
A recovered Ivy League professor turned into RNA enthusiast
An air force veteran that fell in love with life science
A National Academy of Science member turned into an Englishman